Clinical Trial Update: A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease [Phase 4]

View source ↗

Summary

Phase 4 trial updating dose response for inhaled fluticasone propionate in chronic obstructive pulmonary disease completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Fluticasone propionate (Fluticasone propionate)

Snippet

Sponsor: University of Dundee | Conditions: COPD | Phase 4 | Status: COMPLETED | Results posted: 2019-04-09